Press releases

14th October 2021

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform

26th April 2021

Expected to be first RNA epigenetic drug programme globally to enter the clinic in 2022

8th March 2021

Dr. Tsutomu Suzuki is a professor at the department of chemistry and biotechnology in University of Tokyo, Japan.

30th December 2020

Publication provides timely and critical reviews of important topics in medicinal chemistry

26th November 2020

STORM Therapeutics’ will be attending the following virtual conferences.